gefitinib has been researched along with loperamide in 5 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (loperamide) | Trials (loperamide) | Recent Studies (post-2010) (loperamide) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,358 | 196 | 488 |
| Protein | Taxonomy | gefitinib (IC50) | loperamide (IC50) |
|---|---|---|---|
| Cocaine esterase | Homo sapiens (human) | 5.7 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 3.005 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.5 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 9.27 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Histamine H2 receptor | Homo sapiens (human) | 3.081 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.202 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0014 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.337 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.896 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 3.125 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 4.105 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.033 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 0.239 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.628 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cho, WCS; To, KKW; Tong, CWS; Wu, MMX; Yan, VW | 1 |
1 review(s) available for gefitinib and loperamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for gefitinib and loperamide
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells.
Topics: Animals; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gefitinib; Humans; Loperamide; Lung Neoplasms; Mice; Proto-Oncogene Proteins p21(ras) | 2020 |